Folake Aloba
Psychiatric/Mental Health · Hyattsville, MDNPI 1255753489
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 48.8% of the total. Reporting peaked in 2023 at $4,279 and has fallen 72.5% since, to $1,178 in 2025. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$5K
- Johnson & Johnson$890
- Vanda Pharmaceuticals Inc.$882
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$723
- Lundbeck LLC$683
- Otsuka America Pharmaceutical, Inc.$623
- plus $1K from 9 others
What the payments were for
- Speaking & faculty fees$4,05040%
- Travel & lodging$260%
- Food & beverage$6,06859%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 56 | $4,990 |
| Johnson & Johnson | 32 | $890 |
| Vanda Pharmaceuticals Inc. | 43 | $882 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $723 |
| Lundbeck LLC | 38 | $683 |
| Otsuka America Pharmaceutical, Inc. | 30 | $623 |
| Alkermes, Inc. | 22 | $487 |
| AbbVie | 20 | $368 |
| E.r. Squibb & Sons, L.L.C. | 14 | $250 |
| Neurocrine Biosciences, Inc. | 8 | $196 |
| Eisai Inc. | 3 | $44 |
| Indivior Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 1 | $21 |
| Sage Therapeutics, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$3,722
- Austedo XR$450
- ARISTADA$430
- INVEGA SUSTENNA$124
- ARISTADA INITIO$107
How this compares
$10,233 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 14 | $253 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Hyattsville
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.